Philadelphia CyberKnife Offers Noninvasive Treatment to Patients with Lung Tumor Regrowth or Metastases
Noninvasive treatment of tumors that regrow in lung cancer patients is now more possible than ever using CyberKnife® technology. Havertown-based Philadelphia CyberKnife together with Drexel University College of Medicine recently completed a study demonstrating the efficacy of this approach for patients experiencing a recurrence or spread of a lung tumor.
In the last decade, treatment for these diagnoses has progressed using chemotherapy, surgery and external beam radiation therapy, but patients often experience decreased lung functionality following these treatments. The Philadelphia CyberKnife team presented their study at the 2013 National Radiosurgery Society meeting as one of the first of its kind to evaluate this method of treatment for recurrence.
The method uses stereotactic body radiation therapy for recurrent lung cancer patients who have been previously treated with conventional radiation therapy, a process called reirradiation. Results from the study demonstrated patients who received SBRT reirradiation experienced good tumor control at that site and fewer long-term side effects over a three-year period compared with other series of reirradiation.